Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $125.00

Protagonist Therapeutics (NASDAQ:PTGX) had its target price upped by Citigroup from $115.00 to $125.00 in a report released on Thursday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. TD Cowen upped their price objective on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday. Citizens Jmp boosted their target price on Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Barclays increased their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, HC Wainwright raised their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Friday, January 30th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $107.31.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX opened at $98.87 on Thursday. Protagonist Therapeutics has a 52 week low of $39.60 and a 52 week high of $105.69. The company’s fifty day moving average is $87.17 and its 200-day moving average is $81.02. The company has a market capitalization of $6.31 billion, a PE ratio of -48.23 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%. On average, analysts forecast that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insider Buying and Selling

In related news, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the sale, the chief financial officer owned 60,320 shares of the company’s stock, valued at $5,014,401.60. This trade represents a 43.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Arturo Md Molina sold 13,151 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the transaction, the insider owned 84,115 shares of the company’s stock, valued at $6,932,758.30. This trade represents a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 203,167 shares of company stock valued at $16,889,199. Insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PTGX. Rockefeller Capital Management L.P. increased its stake in shares of Protagonist Therapeutics by 10.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,292 shares of the company’s stock valued at $288,000 after buying an additional 312 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Protagonist Therapeutics during the fourth quarter valued at $699,000. Invesco Ltd. boosted its holdings in Protagonist Therapeutics by 56.2% in the fourth quarter. Invesco Ltd. now owns 1,567,840 shares of the company’s stock valued at $136,935,000 after acquiring an additional 564,134 shares during the last quarter. KVP Capital Advisors LP bought a new position in Protagonist Therapeutics in the fourth quarter valued at about $4,629,000. Finally, Virtus Investment Advisers LLC increased its position in Protagonist Therapeutics by 38.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 2,790 shares of the company’s stock worth $244,000 after purchasing an additional 770 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of J&J’s Icotyde for plaque psoriasis materially improves Protagonist’s near-term commercial outlook by triggering milestone payments and future royalty upside tied to Protagonist’s partnered program. Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here’s Why
• Positive Sentiment: Market reaction: coverage highlights a ~6–7% lift tied to the approval and notes the path to royalties; higher-than-average volume suggests institutional interest and re-rating momentum. Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval
• Positive Sentiment: Several major banks raised price targets and reiterated buy/overweight ratings following the approval, providing further upside expectations (Leerink, JPMorgan, Citigroup, Barclays). These analyst upgrades are supporting the stock’s recent run. Analyst coverage roundup (Benzinga) JPMorgan note (TickerReport) Citigroup coverage (Zacks)
• Positive Sentiment: Zacks notes recent momentum and that recent earnings-estimate revisions could support further upside in the near term. Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
• Neutral Sentiment: Broader Wall Street commentary emphasizes that J&J’s approval should create “significant value” for Protagonist, reinforcing sentiment but not guaranteeing cash flow until milestones/royalties are realized. Wall Street says J&J’s FDA-approved psoriasis drug should create significant value for Protagonist
• Negative Sentiment: Key risk: Protagonist reported an earnings and revenue miss in its last report and remains unprofitable with negative margins—meaning the market is pricing future milestone/royalty potential rather than current cash generation. This raises execution and timing risk (milestones may be delayed or smaller than expected).

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.